Анализ акций 531349.BO
53
Нет оценки
Количественный анализ Eyestock не покрывает акции Panacea Biotec Ltd.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Капитализация млрд. $
0.095
Дивидендная доходность
—
Оборот
61.251 млрд
Сайт компании
https://www.panaceabiotec.com/Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi and currently employs 1,093 full-time employees. The firm manufactures a range of paediatric vaccines, including hexavalent vaccine, EasySixTM; pentavalent vaccine, Easyfive- TT and bivalent oral polio vaccine in India and market the same in India, as well as in international markets. The Company’s products include EasySix, Easyfive-TT, Easyfour-TT, EasyFourPol and Bi-OPV. Its pipeline candidates include BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td and DengiAll. The firm is in the process of initiating phase III clinical trials for NucoVac-11, DengiAll and Td vaccines. Its operations are spread across different geographies in India. The firm has two manufacturing facilities located in Lalru, Punjab and Baddi, Himachal Pradesh, and two research and development (R&D) centers in Lalru, Punjab and New Delhi.